| 1. Mechanism of Action |
| Energy Disruption | CCCP-Carbonyl cyanide chlorophenyl hydrazone | MFS- tetA, tetB | H. pylori, Klebsiella spp. | Tetracycline | [98, 99] |
| Synthetic EPI- IITR08027 | MATE- abeM | E. coli, A. baumanii | Fluoroquinolones | [100] |
| PAβN | RND- mexAB-oprM, mexCD-oprJ, mexEF-oprN | P. aeruginosa | LevofloxacinErythromycinStreptomycin | [90, 101] |
| Competitive Inhibition | Verapamil | MATE- dinF and norM | M. tuberculosis | BedaquilineOfloxacin | [102] |
| 1-(1-napthylmethyl)-piperazine (NMP) | RND- acrAB, acrEF | E. coli | LevofloxacinRifampinChloramphenicol | [103] |
| 2. Plant origin |
| Alkaloids | Reserpine (Rawfolia serpentia) | MFS- norA, tetK, BmrMATE- mepA | S. aureusBacillus subtilisStreptococcus pneumoniae | NorfloxacinTetracyclineCiprofloxacin | [104] |
| Piperine (Piper nigram) | ABC transportersMFS- norA | S. aureus, Mycobacterium tuberculosis | CiprofloxacinRifampicin | [105] |
| Conessine (Holarrheaa antidysenterica) | RND- adeIJK, mexAB-oprM | Acinetobacter baumannii | NovobiocinRifampicin | [91] |
| Flavanoids | Baicalein (Thymus vulgaris) | MFS- tetK, norA | Staphylococci | TetracyclineCiprofloxacin | [106, 107] |
| 5’-methoxy-hydnocarpin (Berberis fremontii) | MFS- norA | S. aureus | TetracyclineNorfloxacinBerberine | [108] |
| Genistein (Isoflavone) | MFS- norA | S. aureus | Berberine | [109] |
| Epigallocatechin gallate | MFS- tetK | StaphylococciCamphylobacter | TetracyclineErythromycinCiprofloxacin | [110] |
| Polyphenols | Curcumin (Curcuma longa) | MFS- norARND | S. aureusP. aeruginosa | NorfloxacinCiprofloxacinGentamicin | [111, 112] |
| Coumarin (Mesua ferrea) | MFS- norA | S. aureus | NorfloxacinCiprofloxacin | [113] |
| Phenolic diterpenes | Carnosic acid (Rosmarinus officinalis) | ABC transporter msrA | S. aureus | Erythromycin | [114] |
| Monoterpenoid | Carnosol (Rosmarinus officinalis) | ABC transporter msrAMFS- tetK | S. aureus | Tetracycline | [114] |
| Geraniol (Helichrysum italicum) | RND- acrAB-tolC | Enterobacter aerogenes | Chloramphenicol | [115] |
| Catharanthine (Catharanthus roseus) | RND- mexAB-oprM | P. aeruginosa | TetracyclineStreptomycin | [116] |
| 3. Synthetic origin |
| Quinolone derivatives | Pyridoquinolones | RND- acrAB-tolC | Enterobacter aerogenes | Norfloxacin | [117] |
| Arylpiperidines and aryl piperazine derivatives | Phenylpiperadines | RND- acrAB-tolC | E. coli | Linezolid | [118] |
| Pyridopyrimidine and pyranopyridine derivatives | D2 and D13-9001 | RND- mexAB-oprM | P. aeruginosa | Fluoroquinolones | [119, 120] |
| MBX2319 | RND- acrAB-tolC | E. coli | Fluoroquinolones | [121] |
| Naphthyridine derivatives | 1,8-naphthyridines sulfonamide | MFS- norA | S. aureus | NorfloxacinEthidium bromide | [97] |
| Boronic acid derivatives | 6-(3-Phenylpropoxy) pyridine-3-boronic acid | MFS- norA | S. aureus | CiprofloxacinEthidium bromide | [122] |
| Indole derivatives | 3-amino-6-carboxyl-indole3-nitro-6-amino-indole | RND- acrAB-tolC | E. coli | ChloramphenicolTetracyclineErythromycinCiprofloxacin | [123, 124] |
| 4. Clinically approved drug |
| Hypoglycemic biguanide drug | Metformin | RND- acrAB-tolCMATE- mdtK | K. pneumoniae | Ampicillin-sulbactamMeropenemAmikacin | [125] |
| Tyrosine kinase Inhibitor | Nilotinib | MFS- EmrD | S. aureus | Ciprofloxacin | [86] |
| Ergot alkaloid-vasoconstrictor | Dihydroergotamine | MFS- norA | S. aureus | Ciprofloxacin | [86] |
| 5. Microbial origin |
|
| EA-371α and EA-371d (fermentation extract of Streptomyces spp. | RND- mexAB-oprM | P. aeruginosa | Levofloxacin | [126] |